

Claims

1. Inclusion complex formed of pantoprazole, a salt of pantoprazole with a base, an enantiomer of pantoprazole or a salt of an enantiomer of pantoprazole and cyclodextrin.
2. Inclusion complex according to claim 1 formed of pantoprazole sodium sesquihydrate (= pantoprazole sodium x 1.5 H₂O), (-)-pantoprazole sodium sesquihydrate or pantoprazole magnesium dihydrate.
3. Inclusion complex according to claim 1 or 2, wherein the cyclodextrin is β -cyclodextrin.
4. Method for preparation of an inclusion complex according to any of claims 1 to 3 by reacting pantoprazole with the cyclodextrin in a suitable solvent.
5. Method according to claim 4, wherein the solvent is essentially ethanol.
6. Inclusion complex obtainable according to claim 4.
7. Inclusion complex according to claim 1, which is a 1/1 (pantoprazole/cyclodextrin) inclusion complex.
8. Administration form comprising an inclusion complex according to any of claims 1 to 3 together with suitable pharmaceutical auxiliaries.
9. Inclusion complex according to any of claims 1 to 3 for the treatment or prophylaxis of diseases of disorders originating from increased gastric acid secretion.
10. Method of treating or preventing a condition treatable or preventable with a pyridin-2-ylmethylsulfinyl-1H-benzimidazole, which comprises administering to a subject prone to or afflicted with a condition a pharmaceutically acceptable administration form according to claim 8 comprising an effective amount of the pantoprazole inclusion complex.